Conduit Financial Statements From 2010 to 2026

CDT Stock   0.75  0.18  19.35%   
Analyzing historical trends in various income statement and balance sheet accounts from Conduit Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Conduit Pharmaceuticals' valuation are summarized below:
Market Capitalization
1.7 M
Earnings Share
(179.34)
There are currently one hundred six fundamental signals for Conduit Pharmaceuticals that can be evaluated and compared over time across rivals. All traders should validate Conduit Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

Conduit Pharmaceuticals Total Revenue

2.85 Billion

Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 567.2 K, Selling General Administrative of 14.5 M or Total Revenue of 2.9 B, as well as many indicators such as Price To Sales Ratio of 0.015, Dividend Yield of 0.13 or PTB Ratio of 0.0421. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Conduit Stock
Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.
For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Conduit Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.7 B3.5 B420.4 M
Slightly volatile
Short and Long Term Debt Total1.4 B1.4 B167.2 M
Slightly volatile
Other Current Liabilities352.9 M336.1 M40.9 M
Slightly volatile
Total Current Liabilities732.4 M697.5 M85.2 M
Slightly volatile
Other Liabilities3.9 M4.7 M3.3 M
Slightly volatile
Cash409.4 M389.9 M47.4 M
Slightly volatile
Non Current Assets Total2.2 B2.1 B257.1 M
Slightly volatile
Long Term Debt1.5 M2.3 M1.1 M
Slightly volatile
Cash And Short Term Investments409.4 M389.9 M47.4 M
Slightly volatile
Common Stock Shares Outstanding42.2 M40.2 M4.8 M
Slightly volatile
Liabilities And Stockholders Equity3.7 B3.5 B420.4 M
Slightly volatile
Non Current Liabilities Total1.6 B1.5 B186.3 M
Slightly volatile
Other Current Assets99 M94.3 M11.6 M
Slightly volatile
Total Liabilities2.3 B2.2 B268.9 M
Slightly volatile
Total Current Assets1.4 B1.3 B163.3 M
Slightly volatile
Short Term Debt8.9 M8.5 M1.6 M
Slightly volatile
Common Stock528.1 K503 K62.5 K
Slightly volatile
Deferred Long Term LiabilitiesK4.5 K4.9 K
Slightly volatile
Short and Long Term Debt8.7 M8.3 M1.6 M
Slightly volatile
Intangible Assets300.3 M399.8 M90.5 M
Slightly volatile
Net Receivables254.8 M462.8 M42.6 M
Slightly volatile
Good Will1.1 BBB
Slightly volatile
Short Term Investments295.8 M332.8 M363.2 M
Slightly volatile
Inventory410 M402.3 M350.5 M
Slightly volatile

Conduit Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization567.2 K411.3 K537.6 K
Pretty Stable
Selling General Administrative14.5 M13.8 M4.9 M
Slightly volatile
Other Operating Expenses2.5 B2.3 B286.6 M
Slightly volatile
Research Development135.2 M128.8 M15.9 M
Slightly volatile
Total Operating Expenses695.2 M662.1 M83.5 M
Slightly volatile
Cost Of Revenue926.5 M1.7 B154 M
Slightly volatile

Conduit Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings1.8 M2.8 M1.1 M
Slightly volatile
Begin Period Cash Flow388.8 M370.3 M45.1 M
Slightly volatile
Change To Operating Activities781.2 K536.4 K1.1 M
Slightly volatile
End Period Cash Flow409.4 M389.9 M47.4 M
Slightly volatile
Change To Netincome1.2 M2.3 M669.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.0150.01680.0183
Slightly volatile
Dividend Yield0.130.140.1545
Slightly volatile
Days Sales Outstanding49.7856.061.122
Slightly volatile
Stock Based Compensation To Revenue0.00890.00990.0109
Slightly volatile
Capex To Depreciation1.11.05210.2251
Slightly volatile
EV To Sales0.30.350.3765
Slightly volatile
Inventory Turnover3.353.774.1119
Slightly volatile
Days Of Inventory On Hand69.7778.4885.6666
Slightly volatile
Payables Turnover4.894.65930.8441
Slightly volatile
Research And Ddevelopement To Revenue0.03790.04270.0466
Slightly volatile
Capex To Revenue0.04020.04510.0493
Slightly volatile
Cash Per Share9.359.844460.9304
Slightly volatile
Payout Ratio0.02680.03020.0329
Slightly volatile
Days Payables Outstanding74.4278.3379K
Slightly volatile
Income Quality2.811.4941.577
Slightly volatile
Intangibles To Total Assets0.390.4129303
Slightly volatile
Current Ratio1.181.93460.9545
Slightly volatile
Receivables Turnover4.75.285.7632
Slightly volatile
Graham Number52.5159.0764.4773
Slightly volatile
Capex Per Share3.613.43830.4367
Slightly volatile
Revenue Per Share54.8561.767.3472
Slightly volatile
Interest Debt Per Share31.9933.6746221
Slightly volatile
Debt To Assets0.630.39660.7675
Pretty Stable
Operating Cycle120134147
Slightly volatile
Days Of Payables Outstanding74.4278.3379K
Slightly volatile
Dividend Payout Ratio0.02680.03020.0329
Slightly volatile
Pretax Profit Margin0.07860.08850.0966
Slightly volatile
Operating Profit Margin0.0960.10.1141
Slightly volatile
Ebit Per Revenue0.0960.10.1141
Slightly volatile
Quick Ratio1.461.35780.9371
Slightly volatile
Cash Ratio0.880.5590.5419
Slightly volatile
Operating Cash Flow Sales Ratio0.10.120.1283
Slightly volatile
Days Of Inventory Outstanding69.7778.4885.6666
Slightly volatile
Days Of Sales Outstanding49.7856.061.122
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.890.61630.9756
Slightly volatile
Fixed Asset Turnover3.23.63.9281
Slightly volatile
Debt Ratio0.630.39660.7675
Pretty Stable
Price Sales Ratio0.0150.01680.0183
Slightly volatile
Asset Turnover0.620.70.7662
Slightly volatile
Net Profit Margin0.070.07870.0859
Slightly volatile
Gross Profit Margin0.30.340.3727
Slightly volatile

Conduit Fundamental Market Drivers

Conduit Upcoming Events

19th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Conduit Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Conduit Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Conduit Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue2.7 B2.9 B
Cost Of Revenue1.7 B926.5 M
Stock Based Compensation To Revenue 0.01  0.01 
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue 0.05  0.04 
Revenue Per Share 61.70  54.85 
Ebit Per Revenue 0.10  0.10 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.